Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | XBP1 | P17861 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4878413 | 0.87 | MAPT (0.51) | HTTMAPTXBP1LMNAL3MBTL1 | |
| SCHEMBL14161898 | 0.87 | KMT2A (0.47) | HTTMAPTXBP1LMNAL3MBTL1 | |
| SCHEMBL4010903 | 0.84 | LMNA (0.69) | HTTMAPTXBP1LMNAL3MBTL1 | |
| SCHEMBL4883298 | 0.79 | LMNA (0.60) | LMNASMN1; SMN2KMT2AGAA | |
| SCHEMBL4880877 | 0.79 | MEN1 (0.57) | HTTMAPTLMNACNR1SMN1; SMN2 | |
| SCHEMBL14161927 | 0.79 | MAPT (0.46) | HTTMAPTXBP1LMNAL3MBTL1 | |
| SCHEMBL4009897 | 0.78 | CNR1 (0.65) | HTTMAPTXBP1LMNACNR1 | |
| SCHEMBL4541867 | 0.77 | CNR1 (0.51) | HTTLMNAL3MBTL1USP2CNR1 | |
| SCHEMBL14161843 | 0.77 | KMT2A (0.49) | HTTMAPTXBP1LMNAL3MBTL1 | |
| SCHEMBL8049802 | 0.76 | KMT2A (0.52) | HTTLMNAL3MBTL1CNR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200467-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080200467-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080200467-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200467-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, NCEH1 | HTT 4722/4885MAPT 4647/4885XBP1 3186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.